Abstract 190P
Background
Perioperative chemotherapy(CT) for resectable locally advanced gastric or gastroesophageal junction(G/GEJ) adenocarcinoma has favourable outcomes. Immune checkpoint inhibitors(ICIs) combined with CT have some efficacy in advanced G/GEJ adenocarcinoma. However, the application of ICIs in resectable locally advanced G/GEJ adenocarcinoma remains to be explored. Here, this clinical trial evaluates efficacy and safety of perioperative ICI(Camrelizumab) +CT(XELOX) in resectable locally advanced G/GEJ adenocarcinoma.
Methods
Treatment-naive patients(pts) with cT3-4aN1-3M0 resectable locally advanced G/GEJ adenocarcinoma were recruited to receive Camrelizumab(200mg, iv) on D1, Oxaliplatin(130 mg/m2, iv) on D1 and Capecitabine(1000 mg/m2, po, bid) on D1∼14 Q3W for 4 cycles, followed by surgery and adjuvant Camrelizumab+CT Q3W for 4 cycles. The primary endpoint was pCR rate. The secondary endpoints were MPR rate, ORR, EFS, DFS, safety and feasibility of surgery. The exploratory endpoint was correlation between PD-L1 and TMB expression and efficacy.
Results
From 9/2020 to 1/2023, 46 pts were enrolled, received and completed neoadjuvant treatment, 43 of which had underwent D2 resection. 38 pts received, but 35 pts completed adjuvant treatment. In the ITT analysis set, pCR(TRG1a) occurred in 9 pts(19.6%, 95%CI: 9.9%-34.4%), and MPR(TRG1a/b) occurred in 25 pts(54.3%, 95%CI: 39.2%-68.8%). TRG1b, TRG2 and TRG3 were observed in 16(34.8%), 12 (26.1%) and 6(13.0%) pts, respectively. ORR was 69.6%(95%CI: 54.1%-81.2%), of which 12 pts achieved CR and 20 pts achieved PR. 1-year EFS and DFS achieved 93.101% and 93.108% respectively. Treatment-related adverse events(TRAE) occurred in 91.3% pts, and grade 3 TRAE occurred in 19.6% pts. No grade 4–5 TRAEs were observed. The toxicity and post-surgery complications were limited. Surgical feasibility was not affected.
Conclusions
Among patients with resectable locally advanced G/GEJ adenocarcinoma, neoadjuvant Camrelizumab combined with CT followed by surgery and adjuvant treatment demonstrated good efficacy and safety, providing a new treatment option for locally advanced G/GEJ adenocarcinoma.
Clinical trial identification
NCT05715632.
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract